Skip to content
10-Q

Quarterly Report

Spruce Biosciences, Inc. SPRB

0001193125-26-221605

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 2.75M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.37M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 586.14K sh
Capex Q1 2026 · Mar 31, 2026 $10K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.73M
Long Term Debt Q1 2026 · Mar 31, 2026 $5.46M
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Short Term Debt Q1 2026 · Mar 31, 2026 $1M
Short Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $54.08M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $48.91M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $25.62M
Stockholders Equity Q1 2026 · Mar 31, 2026 $34.65M
Stockholders Equity Q1 2026 · Dec 31, 2025 $42.52M
Stockholders Equity Q1 2026 · Mar 31, 2025 $15.32M
Stockholders Equity Q1 2026 · Dec 31, 2024 $28.82M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.78M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $21.52M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.51M
Current Assets Q1 2026 · Mar 31, 2026 $55.03M
Current Assets Q1 2026 · Dec 31, 2025 $52.11M
Total Assets Q1 2026 · Mar 31, 2026 $56.17M
Total Assets Q1 2026 · Dec 31, 2025 $53.02M
Eps Diluted Q1 2026 · Mar 31, 2026 −$8.94
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$23.95
Eps Basic Q1 2026 · Mar 31, 2026 −$8.94
Eps Basic restated Q1 2026 · Mar 31, 2025 −$23.95
Sga Expense Q1 2026 · Mar 31, 2026 $4.41M
Sga Expense Q1 2026 · Mar 31, 2025 $3.66M
Rd Expense Q1 2026 · Mar 31, 2026 $7.58M
Rd Expense Q1 2026 · Mar 31, 2025 $10.84M
Net Income Q1 2026 · Mar 31, 2026 −$12.27M
Net Income Q1 2026 · Mar 31, 2025 −$14.04M
Operating Income Q1 2026 · Mar 31, 2026 −$11.99M
Operating Income Q1 2026 · Mar 31, 2025 −$14.49M